$CRIS earnings report

Curis reports no revenue and a Q3 2026 net loss of $8.1 million ($1.94 per share), with cash of $5.0 million and runway guided only into Q1 2027. AlphAI read Curis's Q3 FY2026 filing as weak.

Q3 FY2026

AlphAI · Earnings readCRIS · Q3 2026 · ended 2026-09-30

Curis reports no revenue and a Q3 2026 net loss of $8.1 million ($1.94 per share), with cash of $5.0 million and runway guided only into Q1 2027

↓Weak quarter

No revenue was reported for the quarter or the nine months after the Erivedge royalty sale to Oberland in Q4 2025. Net loss widened for the nine months to $40.9 million from $26.9 million. The company states it does not have sufficient cash on hand to support current operations within the next 12 months and expects its funding to last into Q1 2027.

Revenue
—

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenues, net (three months ended September 30, 2026)GAAP—––
Cost of royalties (three months ended September 30, 2026)GAAP—––
Research and development expenses (three months ended September 30, 2026)GAAP$5.6M––
General and administrative expenses (three months ended September 30, 2026)GAAP$3.2M––
Total operating expenses (three months ended September 30, 2026)GAAP$8.75M––
Loss from operations (three months ended September 30, 2026)GAAP−$8.75M––
Total other income (expense) (three months ended September 30, 2026)GAAP$628K––
Net loss (three months ended September 30, 2026)GAAP$8.1M––
Net loss per common share, basic and diluted (three months ended September 30, 2026)GAAP$(1.94)––
Revenues, net (nine months ended September 30, 2026)GAAP—––
Research and development expenses (nine months ended September 30, 2026)GAAP$18.8M––
General and administrative expenses (nine months ended September 30, 2026)GAAP$11.4M––
Total operating expenses (nine months ended September 30, 2026)GAAP$30.21M––
Loss from operations (nine months ended September 30, 2026)GAAP−$30.21M––
Total other income (expense) (nine months ended September 30, 2026)GAAP−$10.69M––
Net loss (nine months ended September 30, 2026)GAAP$40.9M––
Net loss per common share, basic and diluted (nine months ended September 30, 2026)GAAP$(16.77)––
Cash and cash equivalents (as of September 30, 2026)GAAP$5M––
Total assets (as of September 30, 2026)GAAP$18.80M––
Total stockholders' equity (deficit) (as of September 30, 2026)GAAP$2.55M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The company completed a public offering in August 2026.
  • The company completed a private placement in October 2026, with net proceeds of approximately $7.5 million.
  • The filing refers to a January 2026 Private Placement that gave rise to a warrant liability, whose fair value change is cited in other income.

What drove it

  • The company attributes the year-over-year decrease in Q3 research and development expenses primarily to lower employee-related costs, partially offset by an increase in clinical costs.
  • The company attributes the year-over-year decrease in Q3 general and administrative expenses primarily to lower employee-related costs, partially offset by an increase in legal costs.
  • The company attributes the Q3 other income of $0.6 million, compared with other expense of $0.8 million a year earlier, primarily to the change in fair value of the warrant liability associated with the January 2026 Private Placement, partially offset by a decrease in the expense related to the sale of future royalties.
  • The company attributes the nine-month other expense of $10.7 million, compared with $1.6 million a year earlier, to no specific cause in the filing.
  • Revenue comparison: no revenue was reported in Q3 2026 or the nine months ended September 30, 2026, which the company attributes to the sale of Erivedge royalties to Oberland in the fourth quarter of 2025.
  • Clinical progress: 12 patients have been enrolled in the TakeAim CLL study, with initial data expected in December 2026. The TakeAim Lymphoma registrational study reported updated data in July 2026 showing a 26% ORR across all 39 BTKi-experienced patients and 86% ORR across 7 BTK-naive patients.

Concerns

  • No revenue was reported for Q3 2026 or the nine months ended September 30, 2026, after $3,176 thousand in Q3 2025 and $8,305 thousand for the nine months of 2025.
  • Net loss increased to $40.9 million for the nine months from $26.9 million, and the net loss per share was $(16.77) compared with $(43.82).
  • The company states it does not have sufficient cash on hand to support current operations within the next 12 months from the date of the press release.
  • Cash and cash equivalents were $5,014 thousand at September 30, 2026, against accounts payable and accrued liabilities of $15,508 thousand.
  • Total stockholders' equity fell to $2,551 thousand from $5,462 thousand at December 31, 2025.
  • The forward-looking statements section refers to the company's ability to regain and maintain its listing on the Nasdaq Capital Market as a matter that could affect operations and capital raising.

What to watch

  • Initial data from the TakeAim CLL study, which the company expects in December 2026.
  • Whether the company secures additional funding beyond the first quarter of 2027 runway it describes.
  • Next steps for the TakeAim Lymphoma registrational study and any regulatory application for accelerated approval in R/R PCNSL, as the company describes them.
  • Accounts payable and accrued liabilities relative to cash, given the balances reported at September 30, 2026.
  • Status of the company's Nasdaq Capital Market listing, which the filing mentions in its risk language.

Balance sheet and cash flow

  • Cash and cash equivalents: $5,014 thousand as of September 30, 2026, compared with $5,061 thousand as of December 31, 2025.
  • Restricted cash: $544 thousand as of September 30, 2026 and $544 thousand as of December 31, 2025.
  • Total assets: $18,799 thousand as of September 30, 2026, compared with $19,966 thousand as of December 31, 2025.
  • Accounts payable and accrued liabilities: $15,508 thousand as of September 30, 2026, compared with $12,886 thousand as of December 31, 2025.
  • Total liabilities: $16,248 thousand as of September 30, 2026, compared with $14,504 thousand as of December 31, 2025.
  • Total stockholders' equity (deficit): $2,551 thousand as of September 30, 2026, compared with $5,462 thousand as of December 31, 2025.
  • Goodwill: $8,982 thousand at both dates.
  • The company states that its $5.0 million of cash and cash equivalents at September 30, 2026, together with net proceeds of approximately $7.5 million from the October 2026 Private Placement, should enable it to fund existing operations into the first quarter of 2027.
  • The company states that, based on its available cash resources, it does not have sufficient cash on hand to support current operations within the next 12 months from the date of the press release.
  • No operating cash flow, investing cash flow or free cash flow figures are reported in the filing.

Analysis

Curis reported a Q3 2026 net loss of $8.1 million, or $1.94 per share on both a basic and diluted basis, compared with $7.7 million, or $9.86 per share, in Q3 2025. The company reported no revenue for the quarter or the nine months ended September 30, 2026. It attributes this to the sale of Erivedge royalties to Oberland in the fourth quarter of 2025, and the filing reports $3,176 thousand of revenue for Q3 2025 and $8,305 thousand for the nine months of 2025. With no revenue line in 2026, the results reflect only operating expenses and other income or expense.

Operating expenses fell in the quarter. Research and development was $5.6 million against $6.4 million, and general and administrative was $3.2 million against $3.7 million. The company attributes the R&D decline primarily to lower employee-related costs, partly offset by higher clinical costs, and the G&A decline primarily to lower employee-related costs, partly offset by higher legal costs. Total operating expenses were $8,748 thousand against $10,100 thousand. For the nine months, research and development was $18.8 million against $22.4 million, while general and administrative was $11.4 million against $11.2 million. Other items moved in the opposite direction on a nine-month basis: total other expense was $(10,693) thousand against $(1,606) thousand, and the net loss for the nine months was $40.9 million against $26.9 million. The company attributes the Q3 other income to a change in fair value of the warrant liability tied to the January 2026 Private Placement, partly offset by lower expense related to the sale of future royalties. The filing does not state a cause for the nine-month other expense.

The balance sheet shows cash and cash equivalents of $5,014 thousand at September 30, 2026, against $5,061 thousand at December 31, 2025. Total assets were $18,799 thousand, and total stockholders' equity was $2,551 thousand, down from $5,462 thousand. Accounts payable and accrued liabilities rose to $15,508 thousand from $12,886 thousand. The company completed a public offering in August 2026 and a private placement in October 2026 with net proceeds of approximately $7.5 million. It states that these funds, together with existing cash, should fund operations into the first quarter of 2027. The filing also states that the company does not have sufficient cash on hand to support current operations within the next 12 months from the date of the release.

The filing contains no revenue, cash flow or forward financial guidance, so the read rests on the reported losses and the funding statement. The clinical narrative centers on the TakeAim CLL study, with 12 patients enrolled and initial data expected in December 2026, and the TakeAim Lymphoma study, where the July 2026 update reported an ORR of 26% across 39 BTKi-experienced patients and 86% across 7 BTK-naive patients. These are the company's own reported figures and are not a substitute for the financial results above.

Management, verbatim

We are encouraged by our progress in both the TakeAim CLL study and the TakeAim Lymphoma study.

James Dentzer, Chief Executive Officer

Not in the filing

stated, not guessed
  • No forward financial guidance (revenue, operating expenses or cash) is provided in the filing.
  • The previous period's outlook was not provided, so no comparison against prior guidance is possible.
  • Year-over-year and sequential percentage changes are not printed for any line item.
  • Prior-quarter (Q2 2026) figures are not printed in the filing.
  • Operating cash flow, investing cash flow and free cash flow are not reported.
  • Debt balances are not reported beyond the accounts payable and accrued liabilities line.
  • Prior-year and prior-period balance sheet comparisons are only available for December 31, 2025 and are not period-matched to the income statement comparisons.
  • No segment or geographic revenue breakdown is provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CRIS earnings dates

When is Curis's next earnings date?
AlphAI has no date for CRIS yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.